Last reviewed · How we verify
C11-Sodium Acetate
C11-Sodium Acetate is a Small molecule drug developed by Phoenix Molecular Imaging. It is currently in Phase 2 development. Also known as: C11 Acetate PET, Carbon 11, AC-PET.
C11-Sodium Acetate is a small molecule used in PET/CT imaging for studying various conditions, including Prostate Cancer, Prostate Adenocarcinoma, Gliomas, and Multiple Myeloma. It is administered as C11-Sodium Acetate, Carbon-11 Sodium Acetate, or Sodium Acetate C11 PET/CT Imaging in clinical trials.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | C11-Sodium Acetate |
|---|---|
| Also known as | C11 Acetate PET, Carbon 11, AC-PET |
| Sponsor | Phoenix Molecular Imaging |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma (PHASE2)
- C11 Sodium Acetate PET/CT Imaging of PCa
- C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma (PHASE2)
- PET Imaging Characteristics of C11-Acetate in Patients With Recurrent Prostate Carcinoma (PHASE2)
- Clinical Management Decisions for Recurrent Prostate Cancer Patients Based on [11C]Acetate PET Scan
- C11-Sodium Acetate PET/CT Imaging Evaluation in Brain Glioma, Post Therapy Necrosis and Pseudo-progression (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- C11-Sodium Acetate CI brief — competitive landscape report
- C11-Sodium Acetate updates RSS · CI watch RSS
- Phoenix Molecular Imaging portfolio CI
Frequently asked questions about C11-Sodium Acetate
What is C11-Sodium Acetate?
Who makes C11-Sodium Acetate?
Is C11-Sodium Acetate also known as anything else?
What development phase is C11-Sodium Acetate in?
Related
- Manufacturer: Phoenix Molecular Imaging — full pipeline
- Also known as: C11 Acetate PET, Carbon 11, AC-PET
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing